Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Studies suggest that social isolation may exacerbate metabolic dysfunction and impair liver regeneration
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
doi: 10.2147/CPAA.S374741 137 MahapatraMKKaruppasamyMSahooBM
Endocrine Metabolic & Immune Disorders - Drug Targets, 21 (1), 111130
GHK-Cu is non-toxic in vitro at nanomolar to micromolar concentrations
L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats
